Evidence map›Paper›PMID 16247449›Full record

ArticleOncogene2006

RhoB facilitates c-Myc turnover by supporting efficient nuclear accumulation of GSK-3.

M Huang, U Kamasani, G C Prendergast

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Myocardial AKT: the omnipresent nexus.Physiological reviews · 2011
    Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

M HuangLankenau Institute for Medical Research, Wynnewood, PA 19096, USA.
U Kamasani
G C Prendergast
Lankenau Institute for Medical Research · USThomas Jefferson University · US

Funding

ROLE OF RHO IN FARNESYLTRANSFERASE INHIBITOR RESPONSESR01CA082222 · NCI · WISTAR INSTITUTE · PI PRENDERGAST, GEORGE C · 1999 to 2008
$2.4M
RhoB Signaling in Cancer Suppression and Cell SuicideR01CA100123 · NCI · LANKENAU INSTITUTE FOR MEDICAL RESEARCH · PI PRENDERGAST, GEORGE C · 2003 to 2007
$1.7M
NCI NIH HHS CA100123NCI NIH HHS CA82222NCI NIH HHS R01 CA100123
6 · The paper itself

Abstract

The small GTPase RhoB suppresses cancer in part by limiting cell proliferation. However, the mechanisms it uses to achieve this are poorly understood. Recent studies link RhoB to trafficking of Akt, which through its regulation of glycogen synthase kinase-3 (GSK-3) has an important role in controlling the stability of the c-Myc oncoprotein. c-Myc stabilization may be a root feature of human tumorigenesis as it phenocopies an essential contribution of SV40 small T antigen in human cell transformation. In this study we show that RhoB directs efficient turnover of c-Myc in established or transformed mouse fibroblasts and that the attenuation of RhoB which occurs commonly in human cancer is a sufficient cause to elevate c-Myc levels. Increased levels of c-Myc elicited by RhoB deletion increased the proliferation of nullizygous cells, whereas restoring RhoB in null cells decreased the stability of c-Myc and restrained cell proliferation. Mechanistic analyses indicated that RhoB facilitated nuclear accumulation of GSK-3 and GSK-3-mediated phosphorylation of c-Myc T58, the critical site for ubiquitination and degradation of c-Myc. RhoB deletion restricted nuclear localization of GSK-3, reduced T58 phosphorylation, and stabilized c-Myc. These effects were not associated with changes in phosphorylation or localization of Akt, however, differences were observed in phosphorylation and localization of the GSK-3 regulatory Akt-related kinase, serum- and glucocorticoid-inducible protein kinase (SGK). The ability of RhoB to support GSK-3-dependent turnover of c-Myc offers a mechanism by which RhoB acts to limit the proliferation of neoplastically transformed cells.

Indexed as

AnimalsCell Culture TechniquesCell NucleusCell ProliferationCell Transformation, NeoplasticFibroblastsGlycogen Synthase Kinase 3HumansMiceNeoplasmsPhenotypeProto-Oncogene Proteins c-mycrhoB GTP-Binding ProteinTransformation, GeneticGlycogen Synthase Kinase 3Proto-Oncogene Proteins c-mycrhoB GTP-Binding Protein

Identifiers

PMID16247449
OpenAlexW2051538525

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.